Vitamin C and survival among women with breast cancer: A Meta-analysis
+A partir d'une revue systématique de la littérature (10 études prospectives, 17 696 cas de cancer, 1 558 décès par cancer du sein), cette méta-analyse évalue l'association entre une consommation de vitamine C d'origine alimentaire ou une supplémentation en vitamine C et la survie de patientes atteintes d'un cancer du sein
Background : The association between dietary vitamin C intake and breast cancer survival is inconsistent and few studies have specifically examined vitamin C supplement use among women with breast cancer. The purpose of this study was to summarise results from prospective studies on the association between vitamin C supplement use and dietary vitamin C intake and breast cancer-specific mortality and total mortality. Methods : Studies were identified using the PubMed database through February 6, 2014 and by examining the references of retrieved articles. Prospective studies were included if they reported relative risks (RR) with 95% confidence intervals (95% CIs) for at least two categories or as a continuous exposure. Random-effects models were used to combine study-specific results. Results : The ten identified studies examined vitamin C supplement use (n = 6) and dietary vitamin C intake (n = 7) and included 17,696 breast cancer cases, 2791 total deaths, and 1558 breast cancer-specific deaths. The summary RR (95% CI) for post-diagnosis vitamin C supplement use was 0.81 (95% CI 0.72–0.91) for total mortality and 0.85 (95% CI 0.74–0.99) for breast cancer-specific mortality. The summary RR for a 100 mg per day increase in dietary vitamin C intake was 0.73 (95% CI 0.59–0.89) for total mortality and 0.78 (95% CI 0.64–0.94) for breast cancer-specific mortality. Conclusion : Results from this meta-analysis suggest that post-diagnosis vitamin C supplement use may be associated with a reduced risk of mortality. Dietary vitamin C intake was also statistically significantly associated with a reduced risk of total mortality and breast cancer-specific mortality.